Cargando…

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma

Immunotherapy targeting programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1) represents promising treatments for human cancers. Our previous studies demonstrated PD-L1 overexpression in some canine cancers, and suggested the therapeutic potential of a canine chimeric anti-PD-L1 monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maekawa, Naoya, Konnai, Satoru, Nishimura, Maki, Kagawa, Yumiko, Takagi, Satoshi, Hosoya, Kenji, Ohta, Hiroshi, Kim, Sangho, Okagawa, Tomohiro, Izumi, Yusuke, Deguchi, Tatsuya, Kato, Yukinari, Yamamoto, Satoshi, Yamamoto, Keiichi, Toda, Mikihiro, Nakajima, Chie, Suzuki, Yasuhiko, Murata, Shiro, Ohashi, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881100/ https://www.ncbi.nlm.nih.gov/pubmed/33580183 http://dx.doi.org/10.1038/s41698-021-00147-6

Ejemplares similares

Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours
por: Maekawa, Naoya, et al.
Publicado: (2023)

Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
por: Maekawa, Naoya, et al.
Publicado: (2023)

Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma
por: Maekawa, Naoya, et al.
Publicado: (2016)

Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
por: Maekawa, Naoya, et al.
Publicado: (2014)

A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
por: Maekawa, Naoya, et al.
Publicado: (2017)

Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy
por: Maekawa, Naoya, et al.
Publicado: (2022)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma
por: Deguchi, Tatsuya, et al.
Publicado: (2023)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2020)

Upregulation of PD-L1 Expression by Prostaglandin E(2) and the Enhancement of IFN-γ by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection
por: Goto, Shinya, et al.
Publicado: (2020)

Enhancement of Vaccine-Induced T-Cell Responses by PD-L1 Blockade in Calves
por: Okagawa, Tomohiro, et al.
Publicado: (2023)

In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection
por: Nishimori, Asami, et al.
Publicado: (2017)

The enhancement of Th1 immune response by anti-PD-L1 antibody in cattle infected with Mycobacterium avium subsp. paratuberculosis
por: SAJIKI, Yamato, et al.
Publicado: (2020)

Canine Transforming Growth Factor-β Receptor 2-Ig: A Potential Candidate Biologic for Melanoma Treatment That Reverses Transforming Growth Factor-β1 Immunosuppression
por: Takeuchi, Hiroto, et al.
Publicado: (2021)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

Cooperation of PD-1 and LAG-3 in the exhaustion of CD4(+) and CD8(+) T cells during bovine leukemia virus infection
por: Okagawa, Tomohiro, et al.
Publicado: (2018)

Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro
por: Ikebuchi, Ryoyo, et al.
Publicado: (2013)

Anti-Bovine Programmed Death-1 Rat–Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle
por: Okagawa, Tomohiro, et al.
Publicado: (2017)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade
por: Ikebuchi, Ryoyo, et al.
Publicado: (2011)

Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies
por: WATARI, Kei, et al.
Publicado: (2021)

Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in chickens infected with Marek’s disease virus
por: Matsuyama-Kato, Ayumi, et al.
Publicado: (2012)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

Research Note: Characterization of S-Meq containing the deletion in Meq protein's transactivation domain in a Marek's disease virus strain in Japan
por: Murata, Shiro, et al.
Publicado: (2021)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

Development of a high-affinity anti-bovine PD-1 rabbit–bovine chimeric antibody using an efficient selection and large production system
por: Okagawa, Tomohiro, et al.
Publicado: (2023)

Immune inhibitory function of bovine CTLA-4 and the effects of its blockade in IFN-γ production
por: Watari, Kei, et al.
Publicado: (2019)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

Characterization of SpsQ from Staphylococcus pseudintermedius as an affinity chromatography ligand for canine therapeutic antibodies
por: Takeuchi, Hiroto, et al.
Publicado: (2023)

Mandibular vascular hamartoma in a cat
por: TAKAGI, Satoshi, et al.
Publicado: (2018)

Effects of bovine tumor necrosis factor alpha decoy receptors on cell death and inflammatory cytokine kinetics: potential for bovine inflammation therapy
por: Fujisawa, Sotaro, et al.
Publicado: (2019)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

Hemangiosarcoma cells induce M2 polarization and PD-L1 expression in macrophages
por: Gulay, Kevin Christian M., et al.
Publicado: (2022)

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Tick saliva-induced programmed death-1 and PD-ligand 1 and its related host immunosuppression
por: Sajiki, Yamato, et al.
Publicado: (2021)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1
por: NISHIBORI, Shoma, et al.
Publicado: (2023)

Genetic characterization of a Marek’s disease virus strain isolated in Japan
por: Murata, Shiro, et al.
Publicado: (2020)

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cf0s1vbfvvnq2inbaev6lb3rau